Physician profile
Mark C Hand
NPI 1760700041
$719.42
in general payments reported to CMS, 2019-2025
14 companies · $90.10 in 2025
The $90.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.66 · 2022: $143 · 2023: $308 · 2024: $158 · 2025: $90.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $102.35 | 2023-2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $47.17 | 2024-2025 | Contrave, Onzetra Xsail |
| Bayer Healthcare Pharmaceuticals INC. | $39.24 | 2023 | |
| Lilly USA, LLC | $38.38 | 2022-2024 | Zepbound, Jardiance |
| Astellas Pharma US INC | $26.38 | 2024 | Veozah |
| Exact Sciences Corporation | $25.73 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $22.10 | 2025 | |
| Medtronic Vascular, INC. | $20.66 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.99 | 2024 | Breztri |
| Dynavax Technologies Corporation | $17.37 | 2023 | Heplisav-B |
| Abbott Laboratories | $16.13 | 2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $13.55 | 2022 | |
| Glaxosmithkline, LLC. | $13.46 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.